Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Five Prime To Announce First Quarter 2017 Financial Results And Host Conference Call On May 4 April 20, 2017 It's Not Over Yet: Stays Mum on Plans for New Biotech Software Company April 12, 2017 Pfizer Eyes $100 Million Expansion, New Jobs in North Carolina March 7, 2017
Five Prime To Announce First Quarter 2017 Financial Results And Host Conference Call On May 4 April 20, 2017
